Modified glasgow prognostic score in patients with small-cell lung cancer

Kurishima, Koichi; Watanabe, Hiroko; Ishikawa, Hiroichi; Satoh, Hiroaki; Hizawa, Nobuyuki

doi:10.3892/mco.2017.1261

Cited by 23 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies showed mGPS as an independent prognostic factor for OS in SCLC patients. 6 , 16 Although their patient backgrounds were different from ours, their result was consistent with ours. Compared with our study, including 33% (n=32) of mGPS 2, the proportions of mGPS 2 were much lower in those two previous studies: a Chinese and a Japanese study included only 3.1% (n=11) 6 and 22.9% (n=73), 16 respectively.…”

Section: Discussionsupporting

confidence: 88%

“… 6 , 16 Although their patient backgrounds were different from ours, their result was consistent with ours. Compared with our study, including 33% (n=32) of mGPS 2, the proportions of mGPS 2 were much lower in those two previous studies: a Chinese and a Japanese study included only 3.1% (n=11) 6 and 22.9% (n=73), 16 respectively. Unlike our study that enrolled patients treated with chemotherapy alone, the Chinese study included 46.2% of patients treated with thoracic radiotherapy 6 and the Japanese study included 13.5% patients treated with supportive care alone.…”

Section: Discussionsupporting

confidence: 88%

“…Unlike our study that enrolled patients treated with chemotherapy alone, the Chinese study included 46.2% of patients treated with thoracic radiotherapy 6 and the Japanese study included 13.5% patients treated with supportive care alone. 16 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Minami¹,

Ogata²,

Ihara³

et al. 2017

LCTT

View full text Add to dashboard Cite

BackgroundVarious biomarkers have been shown to predict prognosis in various types of cancers. However, these biomarkers have not been studied in advanced small cell lung cancer (SCLC). The modified Glasgow prognostic score (mGPS) is based on serum albumin level and C-reactive protein (CRP). The prognostic nutritional index (PNI) is a combination of serum albumin level and absolute lymphocyte count. This study aimed to evaluate the prognostic value of mGPS and PNI in SCLC.MethodsWe retrospectively reviewed and calculated mGPS and PNI for patients with stage IIIB or IV SCLC who initiated platinum-based combination chemotherapy between November 2007 and June 2016. We compared overall survival (OS) and progression-free survival (PFS) between high and low groups of these two biomarkers. Univariate and multivariate Cox hazard analyses assessed the prognostic value of these biomarkers.ResultsWe reviewed 97 SCLC patients. The OS of patients with mGPS 0–1 and higher PNI was significantly longer than that of those with mGPS 2 and lower PNI. The PFS of mGPS 0–1 was significantly longer than that of mGPS 2, while there was no significant difference in PFS according to PNI. Multivariate analyses found mGPS 0–1 (hazard ratio [HR] 2.34, 95% confidence interval [CI] 1.27–4.31, P<0.01) and higher PNI (HR 0.50, 95% CI 0.31–0.78, P<0.01) as prognostic factors for longer OS. However, neither biomarker was predictive of PFS.ConclusionOur study was a small retrospective study; however, the data demonstrate that pretreatment mGPS and PNI are independent predictors of OS in patients with advanced SCLC. The pretreatment assessment of mGPS and PNI may be useful for identification of patients with poor prognosis. We recommend pretreatment measurement of serum albumin, C-reactive protein, and absolute lymphocyte count.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Minami¹,

Ogata²,

Ihara³

et al. 2017

LCTT

View full text Add to dashboard Cite

show abstract

“…This study design may have resulted in a loss in the identification of tumour type‐specific compounds, but this huge data‐noise has been able to identify trans‐tumoral differences associated with cancer cachexia. Other studies have shown gender differences in metabolic regulation, treatment‐related mortality, and progression of cachexia, being the female sex a favourable prognostic factor . Our study was not designed to evaluate the effect of gender in the genesis nor the evolution of cancer‐related cachexia.…”

Section: Discussionmentioning

confidence: 99%

“…The pathophysiology of cachexia is characterized by a negative energy balance in the body resulting from a combination of inadequate energy intake (anorexia), increased energy expenditure, and systemic inflammation, but abnormal metabolism is the major component . All together result in a clinical phenotype characterized by muscle wasting and body weight loss .…”

Section: Introductionmentioning

confidence: 99%

Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

Cala

Agulló-Ortuño

Prieto-García

et al. 2018

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundCachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The ‘omics’ technologies provide a global view of biological systems. We hypothesize that blood‐based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies.MethodsThis is a cross‐sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at ‘12 de Octubre’ University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC–MS), capillary electrophoresis coupled to mass spectrometry (CE–MS), and liquid chromatography coupled to mass spectrometry (LC–MS). Besides, we performed pathway‐based metabolite analyses to obtain more information on biological functions.ResultsA total of 15 subjects were included in this study, 8 cachectic and 7 non‐cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC–MS), 97% (CE–MS), 96% [LC–MS (positive mode)], and 89% [LC–MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4‐fold change (FC) compared with non‐cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O‐16:0) and lysophosphatidylcholines(20:3) sn‐1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl‐tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others.ConclusionsThese findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non‐cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition.

show abstract

Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents

Freitas

Jacob²,

Tavares³

et al. 2021

Anti-Cancer Drugs

View full text Add to dashboard Cite

Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified Glasgow Prognostic Score (mGPS) and neutrophil-to-lymphocyte ratio (NLR) was assessed. From 77 patients included, 83.2% received at least one prior systemic therapy. Immune-related adverse events (irAE) occurred in 20 patients. A lower mGPS was associated with higher median overall survival (OS), and a lower Eastern Cooperative Oncology Group (ECOG), irAE and fewer metastatic sites with better survival. A trend towards greater OS and progression-free survival (PFS) was stated among patients with NLR <5. mGPS 0 was associated with better survival; ≥3 metastatic sites with worse PFS and OS; ECOG >2 with worse OS and irAE with better survival. Pretreatment mGPS seems to be useful for predicting survival among advanced NSCLC patients treated with anti-programmed cell death 1 drugs, with ECOG performance status, irAE occurrence, and number of metastatic sites acting as survival predictors.

show abstract

Modified glasgow prognostic score in patients with small-cell lung cancer

Cited by 23 publications

References 16 publications

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents

Contact Info

Product

Resources

About